ASSESSING WHETHER THERE IS A CANCER PREMIUM FOR THE VALUE OF A STATISTICAL LIFE

B-Tier
Journal: Health Economics
Year: 2014
Volume: 23
Issue: 4
Pages: 384-396

Authors (3)

W. Kip Viscusi (Vanderbilt University) Joel Huber (not in RePEc) Jason Bell (not in RePEc)

Score contribution per author:

0.670 = (α=2.01 / 3 authors) × 1.0x B-tier

α: calibrated so average coauthorship-adjusted count equals average raw count

Abstract

This article estimates whether there is a cancer risk premium for the value of a statistical life using stated preference valuations of cancer risks for a large, nationally representative US sample. The present value of an expected cancer case that occurs after a one decade latency period is $10.85m, consistent with a cancer premium that is 21% greater than the median value of a statistical life estimates for acute fatalities. This cancer premium is smaller than the premium proposed for policy analyses in the UK and the USA. There is also a greater premium for policies that reduce cancer risks to zero and for risk reductions affecting those who perceive themselves to have a greater than average probability of having cancer. Copyright © 2013 John Wiley & Sons, Ltd.

Technical Details

RePEc Handle
repec:wly:hlthec:v:23:y:2014:i:4:p:384-396
Journal Field
Health
Author Count
3
Added to Database
2026-01-29